THIS IS AN ADVERTISING PROMOTIONA classic American business investment question that is often asked is where is the sizzle? It is a great question to ask - what really adds value to this? In the case of Allergy Therapeutics (AGY:AIM), the answer is the Pollinex Quattro platform and the Virus Like Particle (VLP) Peanut allergy vaccine candidate. Success or significant progress in either of these pi

Since the onset of the Covid-19 pandemic, dividend investors have had a rough old time of it. Quoted company after quoted company has cut or cancelled the shareholder reward.Against this backdrop the investment trust sector has acted as a partial safe haven. Income seekers have long been attracted to investment trusts. Their ability to keep some dividend income aside during good times has helped t

Macroeconomic uncertainties, the return of volatility and political turmoil suggest diversification will prove a key investment watchword in 2019.One way in which investors can diversify portfolios is by allocating funds to UK micro caps, often agile and fast-growing minnows offering better value relative to larger caps; they fly under the radar of big institutional investors and are generally les

In the opening segment of our three-part series we looked at the reasons why UK-based investors should consider exposure to the world's biggest economy and stock market (see Shares, Cover, 4 July). We investigated the political issues that need to be carefully examined and navigated, including the debt debate that continues to rage over the nation's $16 trillion federal deficit. We also explored t

UK mobile giant Vodafone (VOD) has confirmed talks over potentially buying Germany's biggest cable operator, Kabel Deutschland (KD8Gn:DE). Vodafone has been stalking Kabel for several months, eyeing the prospect of bolstering its network infrastructure to better handle the deluge of data that mobile users demand from smartphones and tablets. The market fears a deal could be expensive with the thre